TrialJournal for immunotherapy of cancer2026

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.

Hollis Viray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.